ReviewCancers2021
Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report.Medicine · 2026Article
- Heterogeneity of Hormone Receptors and HER2 in Breast Cancer Cutaneous Metastases: An Institutional Experience.International journal of molecular sciences · 2026Article
- Adipocyte-driven STAT3-ANGPT2-PTGIS axis promotes cutaneous metastasis in breast cancer and represents a targetable pathway.NPJ precision oncology · 2026Article
- Cutaneous metastases of invasive lobular breast cancer as the first clinical manifestation: a case report.The Journal of international medical research · 2025Article
- Systemic and locoregional therapies for cutaneous metastases from breast cancer: state of art and new frontiers in treatment approach.Therapeutic advances in medical oncology · 2025Review
- Case Report: Solitary scalp metastasis after surgery for invasive ductal carcinoma of the breast.Frontiers in oncology · 2025Article
- Case Report: Advanced breast invasive ductal carcinoma with erysipeloid cutaneous metastasis misdiagnosed as erysipelas.Frontiers in oncology · 2025Article
- Molecular alterations and prognosis of breast cancer with cutaneous metastasis.Diagnostic pathology · 2024Article
- Case report: Advanced breast cancer with scalp metastases: a report of two cases.Frontiers in oncology · 2024Article
- A Case Report of Zosteriform Cutaneous Metastases from Breast Carcinoma.Clinical, cosmetic and investigational dermatology · 2024Article
- Topical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers.JID innovations : skin science from molecules to population health · 2023Article
- Cutaneous metastases as a primary manifestation of invasive ductal carcinoma of the breast: a case report.Annals of medicine and surgery (2012) · 2023Article
- Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases.Cancers · 2022Article
- Occult Invasive Lobular Carcinoma Presenting as an Axillary Skin Metastatic Lesion Underwent Neoadjuvant Endocrine Therapy and Surgical Resection: A Case Report and Review of Literature.Breast cancer (Dove Medical Press) · 2022Article
- Zosteriform cutaneous metastases of HER-2 positive breast carcinoma resolved after treatment with lapatinib.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous metastases (CMs) account for 2% of all skin malignancies, and nearly 70% of CMs in women originate from breast cancer (BC). CMs are usually associated with poor prognosis, are difficult to treat, and can pose diagnostic problems, such as in histopathological diagnosis when occurring long after development of the primary tumor. In addition, the molecular differences between the primary tumors and their CMs, and between CMs and metastases in other organs, are not well defined. Here, we review the main clinical, pathological, and molecular characteristics of breast cancer CMs. Identifying molecular markers in primary BC that predict CM and can be used to determine the molecular differences between primary tumors and their metastases is of great interest for the design of new therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.